Related Experiment Video
Updated: Mar 24, 2026
Assaying the Kinase Activity of LRRK2 in vitro
Published on: January 18, 2012
LRRK2 and Parkinson's Disease: From Lack of Structure to Gain of Function
Marian Blanca Ramírez1, Jesus Madero-Perez1, Pilar Rivero-Rios1
1Institute of Parasitology and Biomedicine "Lopez-Neyra", Consejo Superior de Investigaciones Científicas (CSIC), Avda del Conocimiento s/n, 18016 Granada, Spain.
Abstract:
Mutations in LRRK2 comprise the most common cause for familial Parkinson's disease (PD), and variations increase risk for sporadic disease, implicating LRRK2 in the entire disease spectrum. LRRK2 is a large protein harbouring both GTPase and kinase domains which display measurable catalytic activity. Most pathogenic mutations increase the kinase activity, with increased activity being cytotoxic under certain conditions. These findings have spurred great interest in drug development approaches, and various specific LRRK2 kinase inhibitors have been developed. However, LRRK2 is a largely ubiquitously expressed protein, and inhibiting its function in some non-neuronal tissues has raised safety liability issues for kinase inhibitor approaches. Therefore, understanding the cellular and cell type-specific role(s) of LRRK2 has become of paramount importance. This review will highlight current knowledge on the precise biochemical activities of normal and pathogenic LRRK2, and highlight the most common proposed cellular roles so as to gain a better understanding of the cell type-specific effects of LRRK2 modulators.
Insights
Mutations in Leucine-rich repeat kinase 2 (LRRK2) are key to Parkinson's disease (PD). Understanding LRRK2's cell-specific roles is crucial for developing safe and effective PD treatments.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Mutations in Leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of familial Parkinson's disease (PD).
- LRRK2 variations also increase the risk for sporadic PD, highlighting its central role in the disease spectrum.
- LRRK2 possesses both GTPase and kinase domains with measurable catalytic activity, and most pathogenic mutations enhance its kinase function.
Purpose of the Study:
- To review current knowledge on the biochemical activities of normal and pathogenic LRRK2.
- To highlight proposed cellular roles of LRRK2.
- To understand the cell type-specific effects of LRRK2 modulators for improved drug development.
Main Methods:
- Literature review of existing research on LRRK2.
- Analysis of biochemical activities and catalytic functions of LRRK2.
- Synthesis of proposed cellular roles and cell type-specific functions.
Main Results:
- Pathogenic LRRK2 mutations typically increase its kinase activity.
- Increased LRRK2 kinase activity can be cytotoxic under specific conditions.
- LRRK2 is ubiquitously expressed, posing safety concerns for kinase inhibitor approaches due to potential non-neuronal effects.
Conclusions:
- Understanding LRRK2's precise biochemical functions and cellular roles is critical.
- Cell type-specific knowledge of LRRK2 is paramount for developing targeted therapies.
- Further research into LRRK2's cell-specific functions is essential for mitigating safety liabilities in drug development for Parkinson's disease.
Related Concept Videos
01:15Parkinson's Disease: Overview
01:22Lysosomal Hydrolases
01:37Neural Regulation
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...